

May 17, 2020

# **Q4FY20 Result Update**

☑ Change in Estimates | ☑ Target | ■ Reco

### **Change in Estimates**

	Cur	rent	Prev	vious
	FY21E	FY22E	FY21E	FY22E
Rating	Н	OLD	Н	OLD
Target Price	1,	020	1,	061
Sales (Rs. m)	55,675	62,054	57,379	63,953
% Chng.	(3.0)	(3.0)		
EBITDA (Rs. m)	10,022	12,263	10,473	12,791
% Chng.	(4.3)	(4.1)		
EPS (Rs.)	70.0	85.0	73.0	88.5
% Chng.	(4.0)	(3.9)		

#### **Key Financials - Consolidated**

Y/e Mar	FY19	FY20	FY21E	FY22E
Sales (Rs. m)	50,783	56,192	55,675	62,054
EBITDA (Rs. m)	9,158	11,106	10,022	12,263
Margin (%)	18.0	19.8	18.0	19.8
PAT (Rs. m)	7,667	8,187	7,284	8,840
EPS (Rs.)	73.7	78.7	70.0	85.0
Gr. (%)	49.0	6.8	(11.0)	21.4
DPS (Rs.)	25.1	26.0	23.1	28.1
Yield (%)	2.3	2.4	2.2	2.6
RoE (%)	34.7	30.0	22.8	24.0
RoCE (%)	35.6	33.2	27.0	29.1
EV/Sales (x)	2.0	1.8	1.8	1.4
EV/EBITDA (x)	11.4	9.2	9.7	7.3
PE (x)	14.5	13.6	15.3	12.6
P/BV (x)	4.5	3.7	3.3	2.8

Key Data	LTEH.BO   LTTS IN
52-W High / Low	Rs.1,820 / Rs.995
Sensex / Nifty	31,098 / 9,137
Market Cap	Rs.112bn/ \$ 1,477m
Shares Outstanding	105m
3M Avg. Daily Value	Rs.338.03m

### **Shareholding Pattern (%)**

Promoter's	74.62
Foreign	8.37
Domestic Institution	4.88
Public & Others	12.13
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	(12.1)	(24.9)	(36.7)
Relative	(14.1)	(2.5)	(24.5)

### **Aniket Pande**

aniketpande@plindia.com | 91-22-66322300

# **L&T Technology Services (LTTS IN)**

Rating: HOLD | CMP: Rs1,068 | TP: Rs1,020

# Broad based recovery will take time...

### **Quick Pointers:**

- Miss on all counts- Revenue declined by 2% QoQ reported terms & margins declined by 162 bps QoQ to 15.2%.
- We expect FY21 margin to be impacted by lower revenue growth. Challenges in Plant Engineering (higher-margin business) will pressure near-term margin performance; Telecom and Hi-tech is expected to do better, but they are lowmargin verticals.
- We cut our USD revenue estimates of FY21/22E by 3% to factor higher dependence on discretionary spends which led to EPS cut by 4% for FY21/22E. We maintain our HOLD rating with revised TP of Rs. 1020 valued on 12x FY22E earnings.

LTTS reported revenue de-growth of -2.0% QoQ USD 3% below our estimates (Ple:1% QoQ, Cons: 1.2%). Weak revenue growth was on account of steep decline of 8.8% QoQ in plant & engineering. Vertical was impacted by project closures in O&G segment & we believe this vertical will take longer to revive. Reported EBIT margin at 15.2% was down 160 bps QoQ (Ple/Cons: 17.2%), while adjusted for one-off (contribution to PM CARES fund) was 16.5% (-30 bps QoQ). Margin was impacted by lower revenue but aided by strong currency tailwinds. We expect FY21 margin to be impacted by lower revenue. Challenges in Plant Engineering (higher-margin business) will pressure nearterm margin performance; Telecom and Hi-tech is expected to do better, but they are low-margin verticals.

Deal win momentum continued with 9 large wins (1 deal of USD 30 mn, 3 deal of USD10-20 mn), but Q4 witnessed few delayed ramp-ups and project deferrals. Management is witnessing select pockets of green shoots (Medical, Telecom and Hi-tech), but near-term outlook for revenue remains muted. Management expects Q1 to dip, followed by growth in Q2. We projected 4.4% USD revenue decline in FY21E.

We like LTTS from a way longer standpoint given its diversified nature of business, patent filings(IP's) & marque client relationships. However, we believe ER&D business is directly linked to capex & innovation driven nature of the particular business & as there is global macro slowdown across verticals (telecom, manufacturing, auto) companies will spend more on their core operations. We cut our USD revenue estimates of FY21/22E by 3% to factor higher dependence on discretionary spends which led to EPS cut by 4% for FY21/22E. We maintain our HOLD rating with revised TP of Rs. 1020 valued on 12x FY22E earnings.

Revenue de-growth led by Plant Engineering & Auto: LTTS 4Q revenue was our estimates at USD 195mn, -2%/+2.1% QoQ/YoY \$ terms (1.1% QoQ CC). Weak revenue growth was on account of steep decline by 8.8% QoQ in plant & engineering. Management expects slow recovery in Plant & Engineering pertaining to Upstream oil & gas industry. However, we believe

May 17, 2020



Telecom and Hi-tech is expected to do better and will support the topline in the near term. Medical devices segment witnessed strong growth in the quarter (+7.4% QoQ in USD terms) however this segment does not contribute significant share to topline. All other segment posted negative growth, Industrial Products, Telecom & Hi-tech growth slowed by -0.9% QoQ and transportation posted a de growth of -2.2% QoQ USD. **FY20 FCF was significantly weak** at 59% of PAT (94% in FY19) - due to delayed payments

- Pressure on margins, support by currency & export incentive: EBIT margin at 15.2% was down 160 bps QoQ (Ple/Cons: 17.2%), while adjusted for one-off (contribution to PM CARES fund) was 16.5% (-30 bps QoQ). Margin was impacted by lower revenue but aided by strong currency tailwinds. Incentive increased by Rs.194mn QoQ supported the margins by 130 bps. We expect FY21 margin to be impacted by lower revenue. Challenges in Plant Engineering (higher-margin business) will pressure near-term margin performance; Telecom and Hi-tech is expected to do better, but they are low-margin verticals. Utilization dipped ~110 bps to 78.1%; attrition was down 10 bps at 13.8%.
- Deal pipeline looks stable, Plant & Engineering (O&G) may face significant deferrals: Deal win momentum continued, with 9 large wins in Q4FY20 with 1 deals having TCV of USD 30 mn+, 3 deals having TCV value of USD10-20 mn, however Q4 witnessed few delayed ramp-ups and project deferrals. With 2 deals in transportation, 1 deal in Plant & Engineering (CPG) will support the momentum of growth in near term.
- New strategy for COVID-19: As a response to the crisis, LTTS has formed two teams one focusing on resilience and another on growth. Resilience team focuses on bench management, training and collections of receivables. Growth team is proactively engaging discussions on large deals, especially in verticals of Medical and Hi-tech. Management Decision making is prolonged vs pre Covid-19 levels.

Exhibit 1: Q4FY20: Quick view on results


Y/e March (Rs mn)	4QFY20	3QFY20	QoQ gr.	4QFY19	YoY gr.	PL Estimates	Variance
Revenues(USD mn)	195	199	-2.0%	191	2.1%	201	-3.0%
Revenues	14,466	14,230	1.7%	13,431	7.7%	14,721	-1.7%
EBIDTA	2,683	2,864	-6.3%	2,492	7.7%	2,944	-8.9%
EBIDTA margin (%)	18.5%	20.1%	-158bp	18.6%	-1bp	20.0%	-145bp
EBIT	2,198	2,392	-8.1%	2,219	-0.9%	2,503	-12.2%
EBIT Margin (%)	15.2%	16.8%	-162bp	16.5%	-133bp	17.0%	-181bp
PAT	2,063	2,059	0.2%	1,924	7.2%	2,140	-3.6%
PAT margin (%)	14.3%	14.5%	-21bp	14.3%	-6bp	14.5%	-28bp
EPS (Rs)	19.4	19.3	0.3%	18.1	7.0%	20.2	-4.1%

Source: Company, PL



CC revenue decline stood at 1.1% QoQ & growth of 3.4% YoY.


Exhibit 2: De-growth in plant and engineering led to tepid revenue performance



Source: Company, PL

EBIT margin at 15.2% was down 160 bps QoQ (Ple/Cons: 17.2%), while adjusted for one-off (contribution to PM CARES fund) was 16.5% (-30 bps QoQ).

Exhibit 3: EBITDA margin posted a weak performance



Source: Company, PL

**Exhibit 4: Revenues by Verticals (USD Mn)** 

	Q4FY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Transportation	40.4	43.0	45.0	46.7	49.9	52.2	56.7	58.9	62.9	67.7	69.3	71.3	69.8
Growth (%)	-1.1%	6.4%	4.6%	3.7%	6.9%	4.6%	8.6%	3.8%	6.9%	7.5%	2.4%	3.0%	-2.2%
Industrial products	32.5	32.6	32.9	32.9	33.9	34.5	36.5	37.5	36.9	38.0	38.4	38.3	37.9
Growth (%)	1.8%	0.3%	0.7%	0.1%	2.9%	1.8%	5.9%	2.8%	-1.6%	2.9%	1.1%	-0.4%	-0.9%
Telecom & Hi-tech	23.0	25.7	33.8	42.1	47.8	48.5	47.3	50.1	50.1	43.2	40.8	36.9	36.5
Growth (%)	11.2%	11.9%	31.6%	24.5%	13.4%	1.4%	-2.4%	6.0%	0.0%	-13.7%	-5.7%	-9.6%	-0.9%
Process Industry	17.1	17.8	17.8	19.2	19.9	22.8	25.2	26.7	28.1	29.7	32.1	34.3	31.3
Growth (%)	-8.5%	4.3%	0.2%	7.6%	3.9%	14.4%	10.4%	6.3%	5.2%	5.5%	8.1%	6.9%	-8.8%
Medical Devices	8.0	8.8	9.8	9.4	10.5	11.0	11.5	12.4	13.4	15.5	17.4	18.7	20.1
Growth (%)	-1.3%	10.6%	10.4%	-3.2%	11.6%	4.3%	4.9%	8.0%	7.6%	15.8%	12.3%	7.5%	7.4%
Total	121.0	128.0	139.3	151.0	162.0	168.9	177.2	185.7	191.5	194.1	198.0	199.5	195.6
Growth (%)	0.6%	5.8%	8.8%	8.4%	7.3%	4.3%	4.9%	4.8%	3.1%	1.4%	2.0%	0.8%	-2.0%


Source: Company, PL



Transportation vertical has witnessed decline by 220 bps QoQ. However, management believes recovery demand environment especially in Autonomous vehicle.


Decline in utilization (78.2%, -140bps QoQ) may act as a headwind to margins ahead.

**Exhibit 5: Transportation revenues to remain under pressure** 




Source: Company, PL

Exhibit 6: Utilization may act as headwind to margin



Source: Company, PL

**Exhibit 7: Client concentration on top clients remain strong** 



Source: Company, PL

May 17, 2020



**Exhibit 8: Vertical wise revenues** 

Fig in USD mn	4QFY20	3QFY20	QoQ gr.	4QFY19	YoY gr.
Transportation	69.8	71.3	-2.2%	62.9	10.8%
Industrial products	37.9	38.3	-0.9%	36.9	2.7%
Telecom & Hi-tech	36.5	36.9	-0.9%	50.1	-27.1%
Process Industry	31.3	34.3	-8.8%	28.1	11.2%
Medical Devices	20.1	18.7	7.4%	13.4	50.3%
Total Revenues	195.6	199.5	-2.0%	191.5	2.1%
-as a % of total sales					
Transportation	35.7%	35.8%	-10bp	32.9%	280bp
Industrial products	19.4%	19.2%	20bp	19.3%	10bp
Telecom & Hi-tech	18.7%	18.5%	20bp	26.2%	-750bp
Process Industry	16.0%	17.2%	-120bp	14.7%	130bp
Medical Devices	10.3%	9.4%	90bp	7.0%	330bp

Source: Company, PL

**Exhibit 9: Geography-wise revenues** 

Fig in USD mn	4QFY20	3QFY20	QoQ gr.	4QFY19	YoY gr.
North America	119.6	122.0	-2.0%	112.7	6.1%
Europe	32.6	28.1	16.1%	30.6	6.6%
India	25.0	26.3	-4.9%	26.6	-5.9%
RoW	18.0	22.7	-20.9%	21.4	-16.1%
Total Revenues	195.2	199.1	-2.0%	191.3	2.0%
-as a % of total sales					
North America	61.2%	61.2%	0bp	58.9%	230bp
Europe	14.1%	14.1%	0bp	16.0%	-190bp
India	13.2%	13.2%	0bp	13.9%	-70bp
RoW	11.4%	11.4%	0bp	11.2%	20bp

Source: Company, PL

## **Exhibit 10: Client Concentration (%)**

Client contribution	Q4FY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Top 5 clients	23.2	23.8	26.8	28.8	28.6	28.3	28.2	27.4	26.4	24.7	22.9	21.1	19.2
Top 10 clients	35.6	37.0	39.8	41.2	41.4	40.5	39.9	38.9	37.7	36.7	35.7	33.9	31.8
Top 20 clients	51.5	52.6	54.9	56.4	56.7	55.6	55.1	54.4	53.5	52.5	51.3	49.8	48.5

Source: Company, PL

## Exhibit 11: Revenues by Vertical (%)

Contribution by Verticals	Q4FY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Transportation	33.4	33.6	32.3	30.9	30.8	30.9	32.0	31.7	32.9	34.9	35.0	35.8	35.7
Industrial products	26.9	25.5	23.6	21.8	20.9	20.4	20.6	20.2	19.3	19.6	19.4	19.2	19.4
Telecom & Hi-tech	19	20.1	24.3	27.9	29.5	28.7	26.7	27.0	26.2	22.3	20.6	18.5	18.7
Plant Engineering*	14.1	13.9	12.8	12.7	12.3	13.5	14.2	14.4	14.7	15.3	16.2	17.2	16.0
Medical Devices	6.6	6.9	7	6.25	6.5	6.5	6.5	6.7	7.0	8.0	8.8	9.4	10.3
Total	100	100	100	100	100	100	100.0	100.0	100.1	100.1	100.0	100.1	100.1

Source: Company, PL \*Earlier called as Process Industry



Exhibit 12: Revenues by geography (%)

Contribution by geographies	Q4FY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
North America	63.3	64.5	60.8	58.7	57.6	56.3	57.7	57.8	58.9	60.9	61.7	61.2	61.2
Europe	17.3	16.6	16.5	17.2	18.6	18.5	17.2	16.2	16.0	15.6	14.4	14.1	16.7
India	9.2	9.3	10.5	11.5	11.7	12.4	12.5	14.4	13.9	12.8	13.1	13.2	12.8
RoW	10.2	9.6	12.2	12.6	12.1	12.8	12.6	11.6	11.2	10.7	10.7	11.4	9.2
Total	100	100	100	100	100	100	100.0	100.0	100.0	100.0	99.9	99.9	99.9

Source: Company, PL

### **Exhibit 13: Headcount Metrics**

Employee stats	Q4FY17	1QFY18	2QFY18	3QFY18	4QFY18	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20
Total headcount	10,463	10,805	11,532	11,941	12,307	13,081	13,585	14,777	15,140	15,913	16,789	16,787	16,883
Billable	9,537	9,886	10,573	11,009	11,360	12,147	12,604	13,711	14,034	14,755	15,614	15,604	15,667
Sales & Support	926	919	959	932	947	934	981	1,066	1,106	1,158	1,175	1,183	1,216
Voluntary attrition	14%	13.40%	13.40%	13.20%	13.50%	15.40%	15.00%	14.90%	14.80%	15.80%	13.40%	13.90%	13.8%
Net Headcount Add	423	342	727	409	366	774	504	1,192	363	773	876	-2	96

Source: Company, PL

# **Change in Estimates**

We cut our USD revenue estimates of FY21/22E by 3% to factor higher dependence on discretionary spends which led to EPS cut by 4% for FY21/22E. We maintain our HOLD rating with revised TP of Rs. 1020 valued on 12x FY22E earnings.

**Exhibit 14: Change in Estimate** 

Change in Estimates	FY20E	FY21E	FY22E
USD revenues (US\$ m)			
- New	787	752	816
- Old	793	775	841
Change (%)	-0.8%	-3.0%	-3.0%
EBIT Margin			
- New	16.51%	15.8%	17.6%
- Old	17.0%	16.1%	17.8%
Change (%)	-46 bps	-25 bps	-24 bps
Recurring EPS - Fully diluted (Rs)			
- New	77.5	69.0	83.7
- Old	78.4	71.9	87.1
Change (%)	-1.1%	-4.0%	-3.9%

Source: PL



# **Financials**

Income	Statement (	(Rsm)

Income Statement (Rs m)	= 1/4 =	=1/05	======================================	
Y/e Mar	FY19	FY20	FY21E	FY22E
Net Revenues	50,783	56,192	55,675	62,054
YoY gr. (%)	35.5	10.7	(0.9)	11.5
Employee Cost	31,788	33,700	35,076	38,622
Gross Profit	18,995	22,492	20,600	23,432
Margin (%)	37.4	40.0	37.0	37.8
SG&A Expenses	9,837	11,386	10,578	11,170
Other Expenses	-	-	-	-
EBITDA	9,158	11,106	10,022	12,263
YoY gr. (%)	57.6	21.3	(9.8)	22.4
Margin (%)	18.0	19.8	18.0	19.8
Depreciation and Amortization	1,042	1,829	1,211	1,349
EBIT	8,116	9,277	8,811	10,913
Margin (%)	16.0	16.5	15.8	17.6
Net Interest	19	365	40	40
Other Income	2,228	2,091	1,100	1,100
Profit Before Tax	10,325	11,003	9,871	11,973
Margin (%)	20.3	19.6	17.7	19.3
Total Tax	2,630	2,778	2,566	3,113
Effective tax rate (%)	25.5	25.2	26.0	26.0
Profit after tax	7,695	8,225	7,304	8,860
Minority interest	28	38	20	20
Share Profit from Associate	-	-	-	-
Adjusted PAT	7,667	8,187	7,284	8,840
YoY gr. (%)	51.2	6.8	(11.0)	21.4
Margin (%)	15.1	14.6	13.1	14.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	7,667	8,187	7,284	8,840
YoY gr. (%)	51.2	6.8	(11.0)	21.4
Margin (%)	15.1	14.6	13.1	14.2
Other Comprehensive Income	-	_	_	-
Total Comprehensive Income	7,667	8,187	7,284	8,840
Equity Shares O/s (m)	104	104	104	104
EPS (Rs)	73.7	78.7	70.0	85.0

Source: Company Data, PL Research

Balance Sheet Abstract (Rs n	n)			
Y/e Mar	FY19	FY20	FY21E	FY22E
Non-Current Assets				
Gross Block	5,604	6,304	7,004	8,204
Tangibles	2,380	2,800	3,220	3,940
Intangibles	3,224	3,504	3,784	4,264
Acc: Dep / Amortization	3,273	5,102	6,313	7,662
Tangibles	1,349	2,364	3,036	3,786
Intangibles	1,924	2,738	3,277	3,877
Net fixed assets	2,331	1,202	691	542
Tangibles	1,031	436	184	154
Intangibles	1,300	766	507	387
Capital Work In Progress	-	-	-	-
Goodwill	5,365	5,365	5,365	5,365
Non-Current Investments	1,362	1,362	1,362	1,362
Net Deferred tax assets	(8)	(8)	(8)	(8)
Other Non-Current Assets	635	635	635	635
Current Assets				
Investments	5,749	5,849	5,949	6,049
Inventories	-	-	-	-
Trade receivables	10,643	11,777	11,668	13,005
Cash & Bank Balance	2,051	3,336	8,161	15,951
Other Current Assets	3,736	7,585	7,650	4,136
Total Assets	33,534	38,972	43,543	49,307
Equity				
Equity Share Capital	208	208	208	208
Other Equity	24,583	29,517	33,907	39,235
Total Networth	24,791	29,725	34,115	39,443
Non-Current Liabilities				
Long Term borrowings	-	-	-	-
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	702	702	702	702
Trade payables	1,879	2,079	2,060	2,296
Other current liabilities	6,041	6,241	6,441	6,641
Total Equity & Liabilities	33,638	38,972	43,543	49,307

Source: Company Data, PL Research

May 17, 2020



Cash Flow (Rs m)				
Y/e Mar	FY19	FY20	FY21E	FY22E
PBT	10,297	10,965	9,851	11,973
Add. Depreciation	1,042	1,829	1,211	1,349
Add. Interest	(177)	(890)	(620)	(620)
Less Financial Other Income	2,228	2,091	1,100	1,100
Add. Other	-	-	-	-
Op. profit before WC changes	11,162	11,905	10,442	12,703
Net Changes-WC	45	(4,782)	24	(1,301)
Direct tax	(2,630)	(2,778)	(2,566)	(3,113)
Net cash from Op. activities	8,577	4,344	7,899	8,289
Capital expenditures	(1,200)	(700)	(700)	(1,200)
Interest / Dividend Income	196	1,255	660	660
Others	(4,318)	(100)	(100)	(100)
Net Cash from Invt. activities	(5,322)	455	(140)	(640)
Issue of share cap. / premium	3	-	-	-
Debt changes	-	-	-	-
Dividend paid	(3,139)	(3,253)	(2,894)	(3,512)
Interest paid	(19)	(365)	(40)	(40)
Others	30	-	-	-
Net cash from Fin. activities	(3,125)	(3,618)	(2,934)	(3,552)
Net change in cash	131	1,181	4,825	4,096
Free Cash Flow	7,377	3,644	7,199	7,089

Source: Company Data, PL Research

### Quarterly Financials (Rs m)

Y/e Mar	Q1FY20	Q2FY20	Q3FY20	Q4FY20
Net Revenue	13,475	14,021	14,230	14,466
YoY gr. (%)	17.0	10.7	8.1	7.7
Raw Material Expenses	8,354	8,628	8,303	8,415
Gross Profit	5,121	5,393	5,927	6,051
Margin (%)	38.0	38.5	41.7	41.8
EBITDA	2,727	2,832	2,864	2,683
YoY gr. (%)	39.1	23.8	18.5	7.7
Margin (%)	20.2	20.2	20.1	18.5
Depreciation / Depletion	428	444	472	485
EBIT	2,299	2,388	2,392	2,198
Margin (%)	17.1	17.0	16.8	15.2
Net Interest	91	91	89	94
Other Income	565	469	443	614
Profit before Tax	2,773	2,766	2,746	2,718
Margin (%)	20.6	19.7	19.3	18.8
Total Tax	732	704	687	655
Effective tax rate (%)	26.4	25.5	25.0	24.1
Profit after Tax	2,041	2,062	2,059	2,063
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	2,041	2,062	2,059	2,063
YoY gr. (%)	3.0	7.5	10.6	6.6
Margin (%)	15.1	14.7	14.5	14.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	2,041	2,062	2,059	2,063
YoY gr. (%)	3.0	7.5	10.6	7.2
Margin (%)	15.1	14.7	14.5	14.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	2,041	2,062	2,059	2,063
Avg. Shares O/s (m)	106	107	106	106
EPS (Rs)	19.3	19.3	19.5	19.5

Source: Company Data, PL Research

<b>Key Financial Metrics</b>				
Y/e Mar	FY19	FY20	FY21E	FY22E
Per Share(Rs)				
EPS	73.7	78.7	70.0	85.0
CEPS	83.7	96.3	81.7	98.0
BVPS	238.4	285.8	328.0	379.3
FCF	70.9	35.0	69.2	68.2
DPS	25.1	26.0	23.1	28.1
Return Ratio(%)				
RoCE	35.6	33.2	27.0	29.1
ROIC	34.2	32.6	31.5	44.5
RoE	34.7	30.0	22.8	24.0
Balance Sheet				
Net Debt : Equity (x)	(0.3)	(0.3)	(0.4)	(0.5)
Debtor (Days)	76	76	76	76
Valuation(x)				
PER	14.5	13.6	15.3	12.6
P/B	4.5	3.7	3.3	2.8
P/CEPS	76.2	87.7	74.3	89.2
EV/EBITDA	11.4	9.2	9.7	7.3
EV/Sales	2.0	1.8	1.8	1.4
Dividend Yield (%)	2.3	2.4	2.2	2.6

Source: Company Data, PL Research





### **Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Cyient	Hold	450	437
2	HCL Technologies	Hold	548	512
3	Hexaware Technologies	Reduce	219	296
4	Infosys	Hold	668	651
5	L&T Technology Services	Hold	1,061	1,174
6	Larsen & Toubro Infotech	Hold	1,403	1,399
7	Mindtree	Reduce	680	780
8	Mphasis	Accumulate	852	803
9	NIIT Technologies	BUY	1,340	1,190
10	Persistent Systems	Reduce	447	514
11	Redington (India)	BUY	114	117
12	Sonata Software	Accumulate	400	313
13	Tata Consultancy Services	Hold	1,584	1,716
14	TeamLease Services	Hold	3,203	2,487
15	Tech Mahindra	Reduce	478	546
16	Wipro	Sell	169	187
17	Zensar Technologies	Accumulate	246	191

### PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



### **ANALYST CERTIFICATION**

### (Indian Clients)

We/l, Mr. Aniket Pande- MBA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

### **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Aniket Pande- MBA Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com